CN115176159A - 黑素瘤生物标志物 - Google Patents

黑素瘤生物标志物 Download PDF

Info

Publication number
CN115176159A
CN115176159A CN202080058690.XA CN202080058690A CN115176159A CN 115176159 A CN115176159 A CN 115176159A CN 202080058690 A CN202080058690 A CN 202080058690A CN 115176159 A CN115176159 A CN 115176159A
Authority
CN
China
Prior art keywords
autoantibodies
antigens
group
melanoma
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080058690.XA
Other languages
English (en)
Chinese (zh)
Inventor
皮尔·冈宁
彼得拉·布德
汉斯-迪特尔·楚赫特
曼纽尔·布鲁蒂加姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onci Immunity Germany Co ltd
Original Assignee
Onci Immunity Germany Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onci Immunity Germany Co ltd filed Critical Onci Immunity Germany Co ltd
Publication of CN115176159A publication Critical patent/CN115176159A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080058690.XA 2019-06-19 2020-06-19 黑素瘤生物标志物 Pending CN115176159A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908780.8A GB201908780D0 (en) 2019-06-19 2019-06-19 Melanoma biomarkers
GB1908780.8 2019-06-19
PCT/EP2020/067245 WO2020254658A1 (en) 2019-06-19 2020-06-19 Melanoma biomarkers

Publications (1)

Publication Number Publication Date
CN115176159A true CN115176159A (zh) 2022-10-11

Family

ID=67432302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080058690.XA Pending CN115176159A (zh) 2019-06-19 2020-06-19 黑素瘤生物标志物

Country Status (6)

Country Link
US (1) US20220317125A1 (enExample)
EP (1) EP3987289A1 (enExample)
JP (1) JP2022537339A (enExample)
CN (1) CN115176159A (enExample)
GB (1) GB201908780D0 (enExample)
WO (1) WO2020254658A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159127A (zh) * 2023-01-17 2023-05-26 西安交通大学医学院第一附属医院 酸性核糖体蛋白p2在治疗焦虑症中的应用
CN118604339A (zh) * 2024-05-09 2024-09-06 深圳市第二人民医院(深圳市转化医学研究院) Snrpa蛋白检测试剂在制备肝癌诊断试剂盒中的用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
KR102534243B1 (ko) * 2022-12-05 2023-05-31 넥스탭 주식회사 Eomes 단백질을 표적으로 하는 인터페론-γ 조절 물질의 확인방법 및 이 물질을 포함하는 의약
CN118311257B (zh) * 2024-03-22 2025-03-28 安徽师范大学 子宫颈神经内分泌癌标志物在制备子宫颈神经内分泌癌诊断试剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806274A1 (en) * 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
WO2019115480A1 (en) * 2017-12-12 2019-06-20 Protagen Ag Melanoma checkpoint inhibitor detection and treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHUNMEI GUO 等: "ACTB in cancer", 《CLINICA CHIMICA ACTA》, vol. 417, 22 December 2012 (2012-12-22), pages 39 - 44, XP028970356, DOI: 10.1016/j.cca.2012.12.012 *
JAMES LARKIN 等: "Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma", 《N ENGL J MED》, vol. 373, no. 1, 2 July 2015 (2015-07-02), pages 23 - 34, XP055876277, DOI: 10.1056/NEJMoa1504030 *
JESSICA C HASSEL 等: "Prediction of irAEs in ipilimumab-treated melanoma patients based on serum autoantibodies", 《ANNALS OF ONCOLOGY》, vol. 29, 1 October 2018 (2018-10-01), pages 42 - 43 *
PAULINE ZAENKER 等: "A diagnostic autoantibody signature for primary cutaneous melanoma", 《ONCOTARGET》, vol. 9, no. 55, 17 July 2018 (2018-07-17), pages 30539 - 30551, XP055724800, DOI: 10.18632/oncotarget.25669 *
SACHA GNJATIC 等: "Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy", 《JOURNAL FOR IMMUNOTHERAPY OF CANCER》, vol. 5, no. 1, 16 May 2017 (2017-05-16), pages 1 - 18, XP021245142, DOI: 10.1186/s40425-017-0243-4 *
STEFAN VORDENBÄUMEN 等: "Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis", 《ARTHRITIS RESEARCH & THERAPY》, vol. 18, no. 235, 12 October 2016 (2016-10-12), pages 1 - 8 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159127A (zh) * 2023-01-17 2023-05-26 西安交通大学医学院第一附属医院 酸性核糖体蛋白p2在治疗焦虑症中的应用
CN116159127B (zh) * 2023-01-17 2024-04-02 西安交通大学医学院第一附属医院 酸性核糖体蛋白p2在治疗焦虑症中的应用
CN118604339A (zh) * 2024-05-09 2024-09-06 深圳市第二人民医院(深圳市转化医学研究院) Snrpa蛋白检测试剂在制备肝癌诊断试剂盒中的用途

Also Published As

Publication number Publication date
US20220317125A1 (en) 2022-10-06
GB201908780D0 (en) 2019-07-31
WO2020254658A1 (en) 2020-12-24
EP3987289A1 (en) 2022-04-27
JP2022537339A (ja) 2022-08-25

Similar Documents

Publication Publication Date Title
CN115176159A (zh) 黑素瘤生物标志物
US20210231663A1 (en) Melanoma checkpoint inhibitor detection and treatment
CN111337678B (zh) 与肿瘤免疫治疗效果相关的生物标志物及其应用
Ghosh et al. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
Savvateeva et al. Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis
Szczudlik et al. Antititin antibody in early‐and late‐onset myasthenia gravis
AU2016256748A1 (en) Molecular profiling for cancer
WO2016028699A2 (en) Biomarkers for diagnosis and management of neuro-immunological diseases
WO2008156867A1 (en) Biomarkers for the diagnosis of autoimmune disease
US20110207613A1 (en) Biomarkers for lupus
US20150204866A1 (en) Auto-antigen biomarkers for lupus
KR20230074674A (ko) 면역 치료제에 대한 치료 반응성 예측용 바이오마커
JP2023123507A (ja) がんを治療するためのがん免疫
CN110687282B (zh) PD-1和/或p53自身抗体作为肿瘤疗效预测或预后评估的标志物
WO2014195730A2 (en) Auto-antigen biomarkers for lupus
US20190128884A1 (en) Marker sequences for managing the therapy of rheumatoid arthritis patients
EP3407067A1 (en) Method of detecting colitis ulcerosa by detection of autoantibodies
US20220291218A1 (en) Method of improving efficacy of melanoma treatment
DK2551673T3 (en) Methods for detecting cancer infiltration in the central nervous system
JP2014057582A (ja) 細胞傷害活性を予測するための方法及びキット
WO2014122456A1 (en) Diagnosis of rheumatoid arthritis
Koutsonikoli et al. A study on the immunoregulatory role of the PD1 pathway in juvenile idiopathic arthritis
US20130225437A1 (en) Biomarkers of cancer
CN115104029A (zh) 用于检测和监测全身性炎症的非侵入性测定法
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221011